Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27229442 | 0.77 | — | — | |
| SCHEMBL27229417 | 0.75 | PDPK1 (0.37) | SLC9A1KEAP1 | |
| SCHEMBL28137695 | 0.75 | AXL (0.37) | SLC9A1KEAP1 | |
| SCHEMBL27229416 | 0.75 | CHRM4 (0.30) | — | |
| SCHEMBL29303154 | 0.72 | ELANE (0.35) | SLC9A1KEAP1 | |
| SCHEMBL31439795 | 0.70 | — | — | |
| SCHEMBL27965302 | 0.67 | SLC9A1 (0.43) | SLC9A1KEAP1 | |
| SCHEMBL29956191 | 0.67 | MAPK13 (0.38) | SLC9A1KEAP1 | |
| SCHEMBL3712944 | 0.66 | SLC9A1 (0.38) | SLC9A1KEAP1 | |
| SCHEMBL27359770 | 0.64 | PDE10A (0.38) | SLC9A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608820-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Boehringer Ingelheim International GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| CN-120077034-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240174641-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-05-30 | — | — | US | disclosed |
| WO-2024089006-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174641-A1 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | STING1, CGAS, IRF3 | SLC9A1 2694/4885KEAP1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.